IGF-1 LR3
100 mcg vial · lyophilized
Long R3 analog of insulin-like growth factor 1, engineered for an extended half-life and high bioavailability. IGF-1 LR3 substitutes arginine for glutamic acid at position three and adds a 13-amino-acid N-terminal extension, dramatically reducing binding to IGF-binding proteins so more of the peptide stays free and active in plasma.
~20–30 hours
Lyophilized: 2–8 °C. Reconstituted: refrigerate, use within 14 days.
Long R3 analog of insulin-like growth factor 1, engineered for an extended half-life and high bioavailability. IGF-1 LR3 substitutes arginine for glutamic acid at position three and adds a 13-amino-acid N-terminal extension, dramatically reducing binding to IGF-binding proteins so more of the peptide stays free and active in plasma.
View Certificate of Analysis (COA)Who it's for
Recovery-focused researchers studying lean tissue acquisition, satellite-cell activity, and post-injury repair.
Key things to know
- •Administered subcutaneously, typically post-training for nutrient-partitioning research.
- •Cycle 4–6 weeks on, 4 weeks off to preserve IGF-1R sensitivity.
- •Synergizes with HGH and GHRH analogs in published animal studies.
- •Hypoglycemia risk when dosed on an empty stomach — monitor blood glucose in research models.
- •Up to 3× longer half-life vs. native IGF-1 in published pharmacokinetic studies
- •Linked to enhanced myoblast differentiation in vitro
